<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="269">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02316847</url>
  </required_header>
  <id_info>
    <org_study_id>DZNS-EP-1025</org_study_id>
    <nct_id>NCT02316847</nct_id>
  </id_info>
  <brief_title>An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray in Adolescents and Adults With Cluster Seizures</brief_title>
  <official_title>Multi-center, Open-label, Study of Safety and Tolerability of Chronic Intermittent Usage of Diazepam Nasal Spray in Epilepsy Patients With Cluster Seizures, Including Assessment of Olfaction and Reported Changes in Taste.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acorda Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acorda Therapeutics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess long-term safety and tolerability of repeat dose diazepam nasal spray
      in adolescents and adults with cluster seizures, with a focus on potential local effects
      (changes in nasal mucosa, olfaction, and taste).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in nasal mucosa as measured by a focused nasal exam</measure>
    <time_frame>Weeks 12, 24, 36, 48 and 51</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Nasal irritation will be graded &quot;none&quot; to Grade 4 &quot;septal perforation.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Olfactory changes as measured by the Smell Identification Test (SIT)</measure>
    <time_frame>Screening, weeks 12, 24, 36, 48 and 51</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The SIT is a 40-item multiple-choice standardized test of olfactory function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in taste as measured by a taste change questionnaire</measure>
    <time_frame>Weeks 12, 24, 36, 48 and phone visit</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with serious and non-serious Adverse Events (AEs)</measure>
    <time_frame>Up to 13 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Monitoring of AEs will be conducted throughout the study. Adverse events, including serious adverse events, will be recorded in the Case Report Forms (CRFs).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>diazepam nasal spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of diazepam nasal spray is two intranasal sprays; one in each nostril using a nasal spray device. The dose is administered while the subject is sitting up or lying down.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diazepam nasal spray</intervention_name>
    <arm_group_label>diazepam nasal spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of drug-resistant epilepsy

          -  Patients who experience multiple episodes of acute repetitive seizures requiring at
             least one concomitant antiepileptic drug (AED)

          -  Occurrence of at least 3 seizure clusters within the past 12 months, including at
             least one cluster in the 4 months prior to the Screening Visit

          -  A caregiver must consent to participate together with the subject for purposes of
             observation and data collection

          -  The caregiver must be present when the investigational product is administered

          -  Screening body weight between 26 to 111 kg, inclusive

        Exclusion Criteria:

          -  Female subject who is pregnant, breastfeeding, or planning to become pregnant

          -  Presence or history of any abnormality or illness that may affect the absorption,
             distribution, metabolism or elimination of diazepam

          -  Known allergy or hypersensitivity to diazepam, related drugs, or any of the
             formulation components

          -  Positive screening test for ethanol or other drugs of abuse

          -  Unable to receive medications intranasally
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Squillacote, MD</last_name>
    <role>Study Director</role>
    <affiliation>Acorda Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Acorda Site #227</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy Wieser</last_name>
      <phone>480-342-3775</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acorda Site #204</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Davis</last_name>
      <phone>501-227-6179</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acorda Site #206</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracie Junker</last_name>
      <phone>407-293-1122</phone>
      <phone_ext>222</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acorda Site #231</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon DeVore</last_name>
      <phone>850-656-6377</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acorda Site #201</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara McTigue</last_name>
      <phone>813-259-0826</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acorda Site #217</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patty Ray</last_name>
      <phone>706-721-6260</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acorda Site #232</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Adanpo</last_name>
      <phone>808-372-9688</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acorda Site #225</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debi Kocks</last_name>
      <phone>260-436-3391</phone>
      <phone_ext>2143</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acorda Site #226</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Hackett</last_name>
      <phone>515-956-4079</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acorda Site #202</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivana Tyrlikova</last_name>
      <phone>240-480-9665</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acorda Site #208</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Swetha Chinta</last_name>
      <phone>617-632-8944</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acorda Site #212</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Jackson</last_name>
      <phone>617-919-8686</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acorda Site #214</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nichelle Llewellyn</last_name>
      <phone>617-732-5423</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acorda Site #216</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer McIntire</last_name>
      <phone>816-932-7985</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acorda Site #205</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caren Hein</last_name>
      <phone>314-566-5930</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acorda Site #222</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Munazza Malik</last_name>
      <phone>201-343-6676</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acorda Site #223</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronique Ruppe</last_name>
      <phone>646-558-0877</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acorda Site #230</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chad Sorenson</last_name>
      <phone>503-494-9633</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acorda Site #203</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Hamrick</last_name>
      <phone>843-792-3855</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acorda Site #218</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>372322551</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Osborn</last_name>
      <phone>615-322-8817</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acorda Site #221</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Aguilar</last_name>
      <phone>972-707-8378</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acorda Site #215</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn O'Hara</last_name>
      <phone>804-828-3862</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acorda Site #224</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole Burton</last_name>
      <phone>425-970-1307</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Acorda Site #210</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimaya Chaubal</last_name>
      <phone>608-262-7115</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 6, 2015</lastchanged_date>
  <firstreceived_date>December 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cluster Seizures</keyword>
  <keyword>Seizures</keyword>
  <keyword>Clusters</keyword>
  <keyword>Acute repetitive seizures</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
